-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Recently, the Hejie academician team published the data of "2016 China Cancer Incidence and Death Statistics" in JNCC.
Overall, the incidence of cancer in China is still increasing
.
With the intensified aging of the population and the escalating consumption level of residents, the anti-tumor market has a very broad prospect
.
According to data from Minet.
com, in 2020, the sales of terminal anti-tumor drugs in China's public medical institutions have exceeded 100 billion yuan, a year-on-year increase of 9.
63%
.
In the face of a considerable market blue ocean, in recent years, a large number of domestic and foreign pharmaceutical companies have been attacking the anti-tumor drug market, increasing investment in research and development, strengthening cooperation between companies, and enriching the company's product pipeline
.
Recently, BeiGene announced that it has completed the approval of five anti-tumor products, Novadabrafenib, trametinib, pazopanib, everolimus, and ceritinib that have been approved and included in the medical insurance drug list.
The license was introduced into the transaction and will be marketed, promoted and sold in designated areas within China (approximately 13,000 hospitals covering approximately 500,000 cancer patients)
.
Up to now, BeiGene has 16 approved antitumor drugs in China
.
On March 14, Hengrui Medicine announced that its two products, SHR-A1811 and SHR-1701 injection for injection, have been approved for clinical use and will start clinical research as soon as possible
.
In recent years, Hengrui Medicine has gradually made efforts in innovative drugs, and its product pipeline includes Erecoxib Tablets, Camrelizumab for Injection, Dalcilizate Isethionate Tablets, Proline Henggliflozin Tablets, etc.
10 innovative drugs have been approved for marketing, and over 50 innovative drugs are under clinical development
.
According to statistics, from 2021 to mid-February 2022, Hengrui Medicine has applied for clinical trials for at least 27 drugs for the first time, of which at least 15 drugs are indicated for tumors
.
In addition to BeiGene and Hengrui, there are many pharmaceutical companies currently holding multiple varieties of anti-tumor drugs under research, such as Chi-Med Pharmaceuticals, Shouyao Holding, and Junshi Biology
.
Chi-Med focuses on "First in class".
According to the data from Minet, Chi-Med has more than 20 new drug R&D projects, most of which are original class 1 small molecule drugs.
The product pipeline covers tumors, immune regulation, digestion and metabolism.
, skin and hematopoietic system and other therapeutic areas, among which there are about 11 candidate drug projects under development with rapid progress, mainly anti-tumor drugs
.
Shouyao Holding has 22 products under development, covering key tumor indications such as non-small cell lung cancer, colorectal cancer, liver cancer, breast cancer, pancreatic cancer, and lymphoma, as well as therapeutic areas that are currently receiving attention such as diabetes
.
It is reported that in the future, Shouyao Holding will focus on creating a differentiated competitive advantage in the whole process, major diseases and multiple categories, and strive to have more than 2 innovative drug pipelines to apply for clinical trials every year
.
Junshi Bio is a leading PD-1 enterprise in China, and has been deeply engaged in the research and development of innovative tumor drugs
.
The company has a rich reserve of tumor immunity products.
In addition to the self-developed toripalimab, the company also actively introduces drugs such as IL-2, IL-21, CD39, TROP2 ADC, etc.
, which has better expanded the company's product richness in the tumor field.
.
At present, there are 4 product pipelines in the approval/clinical phase III stage, covering the three major fields of tumor, autoimmunity, and metabolism, involving PARP, PCSK9, TNF-α, VEGF and other popular targets
.
In the context of a large number of pharmaceutical companies tackling key issues in the field of oncology and the acceleration of new drug approval and review, this is good news for the majority of patient groups
.
In the future, with the continuous enrichment of treatment plans and treatment methods and the advancement of medical insurance, the survival rate of domestic cancer patients is expected to continue to improve, and the quality of life will also improve
.
According to the goal of "Healthy China 2030", by 2030, the health management of chronic diseases for the whole population and the whole life cycle will be realized, and the overall 5-year cancer survival rate will increase by 15%
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
Overall, the incidence of cancer in China is still increasing
.
With the intensified aging of the population and the escalating consumption level of residents, the anti-tumor market has a very broad prospect
.
According to data from Minet.
com, in 2020, the sales of terminal anti-tumor drugs in China's public medical institutions have exceeded 100 billion yuan, a year-on-year increase of 9.
63%
.
In the face of a considerable market blue ocean, in recent years, a large number of domestic and foreign pharmaceutical companies have been attacking the anti-tumor drug market, increasing investment in research and development, strengthening cooperation between companies, and enriching the company's product pipeline
.
Recently, BeiGene announced that it has completed the approval of five anti-tumor products, Novadabrafenib, trametinib, pazopanib, everolimus, and ceritinib that have been approved and included in the medical insurance drug list.
The license was introduced into the transaction and will be marketed, promoted and sold in designated areas within China (approximately 13,000 hospitals covering approximately 500,000 cancer patients)
.
Up to now, BeiGene has 16 approved antitumor drugs in China
.
On March 14, Hengrui Medicine announced that its two products, SHR-A1811 and SHR-1701 injection for injection, have been approved for clinical use and will start clinical research as soon as possible
.
In recent years, Hengrui Medicine has gradually made efforts in innovative drugs, and its product pipeline includes Erecoxib Tablets, Camrelizumab for Injection, Dalcilizate Isethionate Tablets, Proline Henggliflozin Tablets, etc.
10 innovative drugs have been approved for marketing, and over 50 innovative drugs are under clinical development
.
According to statistics, from 2021 to mid-February 2022, Hengrui Medicine has applied for clinical trials for at least 27 drugs for the first time, of which at least 15 drugs are indicated for tumors
.
In addition to BeiGene and Hengrui, there are many pharmaceutical companies currently holding multiple varieties of anti-tumor drugs under research, such as Chi-Med Pharmaceuticals, Shouyao Holding, and Junshi Biology
.
Chi-Med focuses on "First in class".
According to the data from Minet, Chi-Med has more than 20 new drug R&D projects, most of which are original class 1 small molecule drugs.
The product pipeline covers tumors, immune regulation, digestion and metabolism.
, skin and hematopoietic system and other therapeutic areas, among which there are about 11 candidate drug projects under development with rapid progress, mainly anti-tumor drugs
.
Shouyao Holding has 22 products under development, covering key tumor indications such as non-small cell lung cancer, colorectal cancer, liver cancer, breast cancer, pancreatic cancer, and lymphoma, as well as therapeutic areas that are currently receiving attention such as diabetes
.
It is reported that in the future, Shouyao Holding will focus on creating a differentiated competitive advantage in the whole process, major diseases and multiple categories, and strive to have more than 2 innovative drug pipelines to apply for clinical trials every year
.
Junshi Bio is a leading PD-1 enterprise in China, and has been deeply engaged in the research and development of innovative tumor drugs
.
The company has a rich reserve of tumor immunity products.
In addition to the self-developed toripalimab, the company also actively introduces drugs such as IL-2, IL-21, CD39, TROP2 ADC, etc.
, which has better expanded the company's product richness in the tumor field.
.
At present, there are 4 product pipelines in the approval/clinical phase III stage, covering the three major fields of tumor, autoimmunity, and metabolism, involving PARP, PCSK9, TNF-α, VEGF and other popular targets
.
In the context of a large number of pharmaceutical companies tackling key issues in the field of oncology and the acceleration of new drug approval and review, this is good news for the majority of patient groups
.
In the future, with the continuous enrichment of treatment plans and treatment methods and the advancement of medical insurance, the survival rate of domestic cancer patients is expected to continue to improve, and the quality of life will also improve
.
According to the goal of "Healthy China 2030", by 2030, the health management of chronic diseases for the whole population and the whole life cycle will be realized, and the overall 5-year cancer survival rate will increase by 15%
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
